BACKGROUND: Treatment of high‐risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …

Although both surgery and radiation are potential curative options for men with clinically
localized prostate cancer, a significant proportion of men with high-risk and locally advanced …

Purpose: To determine the clinical, pathologic, and molecular effects of neoadjuvant
docetaxel chemotherapy in high-risk localized prostate cancer. Experimental Design …

Purpose: We assessed pathological outcomes as well as the feasibility of combined
docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing …

BACKGROUND: Patients with locally advanced or organ confined, high risk, prostate cancer
are at significant risk of having disease recurrence despite definitive local therapy. We …

BACKGROUND. The objective of the current study was to determine the histologic and
molecular changes that occurred in patients with high‐risk, localized prostate cancer (PCa) …

Effective treatment options for high-risk localized prostate cancer are limited. Patients at high
risk for recurrence include those with biopsy Gleason scores of 8 to 10, prostate specific …

Multimodal strategies combining local and systemic therapy offer the greatest chance of cure
for many with men with high-risk prostate cancer who may harbor occult metastatic disease …

OBJECTIVES: To perform a Phase II trial of docetaxel administered on a weekly schedule for
6 weeks before radical prostatectomy (RP) in patients with locally advanced prostate cancer …

Background Patients with locally advanced prostate cancer (PCa) have worse outcomes
after radical prostatectomy (RP) than patients with more favorable parameters. We …